文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

保留勃起组织的前列腺癌调强放疗3期随机前瞻性试验长期结果

Long-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue-Sparing Intensity-Modulated Radiation Therapy for Men With Clinically Localized Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-12-23

这项单中心、前瞻性、单盲3期随机试验纳入117例低至中危临床T1a-T2c前列腺腺癌患者,比较保留勃起组织调强放疗(ETS-IMRT)与标准调强放疗(s-IMRT)。24个月勃起功能保留率两组无显著差异(意向治疗分析37.1% vs 31.5%,P=.53),5年生化失败无差异(91.8% vs 90.7%,P=.77),中位随访7.4年,急慢性胃肠及泌尿生殖毒性无差异。

要点

  • ETS-IMRT将阴茎球D90限制≤15 Gy、海绵体D90限制≤7 Gy,安全可行。
  • 24个月意向治疗分析勃起功能保留率ETS-IMRT组37.1% vs s-IMRT组31.5%(P=.53)。
  • 5年生化失败无差异:ETS-IMRT组91.8% vs s-IMRT组90.7%(P=.77),中位随访7.4年。

核心结论

  • 严格限制阴茎球和海绵体剂量的ETS-IMRT安全可行,但该计划技术未显示对2年勃起功能保留结局有影响,且检测差异的把握度有限。

研究设计与样本

  • 单中心、前瞻性、单盲3期随机试验,纳入117例低至中危临床T1a-T2c前列腺腺癌患者;62例接受ETS-IMRT,54例接受s-IMRT,1例未接受放疗;所有患者接受74至80 Gy分37至40次的根治性IMRT。

主要发现

  • 意向治疗分析中,24个月勃起功能保留率ETS-IMRT组37.1% vs s-IMRT组31.5%(P=.53)。
  • 85例可评估患者中,ETS-IMRT组47.9% vs s-IMRT组46.0%保持勃起功能(P=.86)。
  • PDE5抑制剂启用率ETS-IMRT组41.7% vs s-IMRT组35.1%(P=.54)。
  • 全部入组患者5年生化失败无差异:ETS-IMRT组91.8% vs s-IMRT组90.7%(P=.77),中位随访7.4年。
  • 急性或晚期胃肠及泌尿生殖毒性无差异。

关键数值与推荐

  • ETS-IMRT的额外计划约束为阴茎球D90≤15 Gy、海绵体D90≤7 Gy。
  • 放疗剂量为74至80 Gy分37至40次。
  • 85例可评估患者中勃起功能保留率ETS-IMRT组47.9% vs s-IMRT组46.0%(P=.86)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出检测差异的把握度有限。
  • 非计划性符合方案分析显示,超过勃起组织保留约束与符合约束的患者在勃起功能保留及次要终点上无差异,但把握度受脱落和非计划剂量学交叉限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to determine whether limiting the doses delivered to the penile bulb (PB) and corporal bodies with intensity modulated radiation therapy (IMRT) preserves erectile function compared with standard IMRT in men with prostate cancer. METHODS AND MATERIALS: A total of 117 patients with low- to intermediate-risk, clinical T1a-T2c prostate adenocarcinoma were enrolled in a single-institution, prospective, single-blind, phase 3 randomized trial. All received definitive IMRT to 74 to 80 Gy in 37 to 40 fractions and standard IMRT (s-IMRT) or erectile tissue-sparing IMRT (ETS-IMRT), which placed additional planning constraints that limited the D90 to the penile bulb and corporal bodies to ≤15 Gy and ≤7 Gy, respectively. Erectile potency was assessed with components of the International Index of Erectile Function and phosphodiesterase type 5 inhibitor (PDE5) medication records. RESULTS: Sixty-two patients received ETS-IMRT, and 54 received s-IMRT; 1 patient did not receive radiation therapy. Before treatment, all patients reported erectile potency. No patients received androgen deprivation therapy. In the intention-to-treat analysis, treatment arms did not differ in potency preservation at 24 months (37.1% ETS-IMRT vs 31.5% s-IMRT, P = .53). Of 85 evaluable patients with International Index of Erectile Function and PDE5 medication follow-up, erectile potency was seen in 47.9% of patients in the ETS-IMRT arm and 46.0% of patients in the s-IMRT arm (P = .86). PDE5 inhibitors were initiated in 41.7% of ETS-IMRT patients and 35.1% of s-IMRT patients (P = .54). Among all patients enrolled, there was no difference in freedom from biochemical failure between those treated with ETS-IMRT and s-IMRT (5-year 91.8% vs 90.7%, respectively, P = .77), with a median follow-up of 7.4 years. There were no differences in acute or late gastrointestinal or genitourinary toxicity. An unplanned per-protocol analysis demonstrated no differences in potency preservation or secondary endpoints between patients who exceeded erectile tissue-sparing constraints and those who met constraints, although power was limited by attrition and unplanned dosimetric crossover. CONCLUSIONS: ETS-IMRT that strictly limits dose to the penile bulb and corporal bodies is safe and feasible. Use of this planning technique did not show an effect on potency preservation outcomes at 2 years, though power to detect a difference was limited.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zhang E, Ruth KJ, Buyyounouski MK, et al. Long-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue-Sparing Intensity-Modulated Radiation Therapy for Men With Clinically Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 36566906. doi:10.1016/j.ijrobp.2022.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。